Drugs that contain radioactive isotopes — forms of chemical elements that emit radiation — are known as radiopharmaceuticals. Radioisotopes have been used to treat cancer as far back as the 1940s, but the field has really taken off just in the past few years as researchers explore their potential in cancer. How are radiopharmaceuticals used … Read more
Stymied and disoriented. That’s one way to describe the state of the immune system in some patients with cancer. T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led … Read more
Discovering new cancer treatment can sometimes be a matter of connecting the dots between new pathways and old drugs. That was the case in a new paper in the TKTK issue of Clinical Cancer Research co-authored by Kent Mouw MD, PhD, co-director of Dana-Farber’s Bladder Cancer Center. Mouw and his team found a promising way … Read more
Chuck Stravin carries a white three-ring binder to all of his oncology appointments. Inside are his appointment notes, information about his treatment history, and the latest research and advancements regarding his disease. Nestled alongside these documents also sits a family photo of Stravin, his wife Liz, and their four daughters. Stravin’s family has been instrumental … Read more
A woman recently came to Bradley McGregor, MD, an oncologist at Dana-Farber Cancer Institute, in severe pain with extreme fatigue. Her squamous cell bladder cancer, a rare type for which traditional treatment is generally less effective, had advanced, and it appeared that she had no other options. But timing is everything. McGregor was conducting a … Read more
The management of advanced prostate cancer is rapidly evolving with the application of precision treatments based on genomic testing of tumors’ altered DNA. With recent biomarker-driven drug approvals and increased clinical use of genomic testing, there are a number of opportunities to expand upon this framework. Researchers are calling for increased collaboration and new strategies. … Read more
Husband and wife Ken Deutsch and Amy Green like to say they’re now “chasing the tail” of the bell curve. They have each had to grapple with cancer, as well as multiple setbacks and even recurrences. However, thanks to the care they’ve received at Dana-Farber — along with the support they’ve had from each other … Read more
Scientists are gratified when a clinical trial reveals whether one treatment — often an experimental therapy or drug combination — is superior to another. But researchers then often look more deeply into the data, searching for characteristics of tumors associated with a treatment’s effectiveness, or lack of it. In today’s world of precision medicine, identifying … Read more
Throughout our lifetimes, our bodies are constantly repairing or replacing our billions of cells. During this process, mistakes routinely happen, but generally one mishap in the duplication procedure is not an issue. This mistake will simply often cause the cell to die. However, in rare instances, a cumulation of errors can help the cell bypass … Read more
Before the use of CT scans (formerly known as CAT scans), back pain was associated with the diagnosis of kidney cancer — but this is no longer the case. Today, general cancer screening often catches kidney cancer before this symptom occurs, according to Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology … Read more
For designers of targeted drugs, the biggest bullseye in prostate cancer has been the androgen receptor — a specialized net on prostate cells that snares androgen molecules to spur the cells’ growth. Drugs that block, or inhibit, the receptor can halt the cancer, but not all patients benefit from them, and nearly all those who … Read more
Early on an October morning, Shaun Tierney started a promising new treatment for his stage IV kidney cancer. Anxious to tell his longtime oncologist, he texted Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber. What he didn’t expect was that Choueiri would have his own big news: “Kaelin … Nobel … Read more
There was a time when Bradley McGregor, MD, had what many would consider an unusual morning routine for an oncologist. Getting ready for work included putting on nearly 60 pounds of body armor, donning a tactical helmet, and grabbing his assault rifle before heading out the door. His commute took him from an American compound, … Read more
When he was 67 years old, Barry Polsky said “I do” for the first time in his life when he married his wife, Randi. One year later, the retired high school teacher and lifelong baseball fan was offered one of his dream jobs as a tour guide at Fenway Park. And earlier this year, at … Read more
African Americans have a 60 percent higher incidence of prostate cancer compared to other ethnic groups, and a 150 percent higher risk of dying from it — in part because African Americans tend to have a more aggressive form. They are also more likely to develop prostate cancer at an earlier age and to have … Read more
Medically reviewed by Bradley McGregor, MD Kidney cancer occurs when the cells of the kidney acquire abnormal mutations in their DNA and then multiply. These cells may accumulate and form a tumor; in some cases, they metastasize and spread elsewhere in the body. Can I inherit kidney cancer? A family history of kidney cancer does … Read more
Medically reviewed by Himisha Beltran, MD Prostate cancer, when diagnosed early, can be a very treatable disease. Even advanced prostate cancer has treatment options. But some advanced, metastatic prostate cancers become resistant to standard therapies by shapeshifting into a different type of cancer, called small cell neuroendocrine prostate cancer. These neuroendocrine tumors tend to be … Read more
Cancer is often fueled by hormones, including the male sex hormone testosterone, which spur tumor growth in most forms of prostate cancer. Doctors can defuse this destructive relationship, typically with drugs (or sometimes surgery), but frequently, the tumors adapt or evolve, devising ways to incite cancer growth even in the absence of hormone-driven signals. These … Read more
Urinary problems are more common among older adults, when incontinence and urinary-tract infections become more prevalent and bladder cancer risk rises. About 9 out of 10 bladder cancer patients are above the age of 55, according to the American Cancer Society. The symptoms of bladder cancer can mirror those of other conditions, so it’s important … Read more